Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C

Journal of Hepatology

Volumn 68, Issue 4, 2018, Pages 663-671

  Buggisch, Peter ^a   Vermehren, Johannes ^b   Mauss, Stefan ^c   Günther, Rainer ^d   Schott, Eckart ^e   Pathil, Anita ^f   Boeker, Klaus ^g   Zimmermann, Tim ^h   Teuber, Gerlinde ⁱ   Vornkahl, Heike Pfeiffer ^j   Simon, Karl Georg ^k   Niederau, Claus ^l   Wedemeyer, Heiner ^m   Zeuzem, Stefan ^b  

^a Ifi Institute for Interdisciplinary Medicine   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Center for HIV and Hepatogastroenterology   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g Hepatologische Praxis   (Germany)

^h UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

ⁱ Hepatologische Praxis   (Germany)

^j E factum GmbH   (Germany)

^k Hepatologische Praxis   (Germany)

^l St Josef Hospital Oberhausen   (Germany)

^m HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

8 week treatment; German Hepatitis C Registry; HCV genotype 1; Ledipasvir sofosbuvir; Real world

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; INTERFERON; LEDIPASVIR PLUS SOFOSBUVIR; SIMEPREVIR; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR; SOFOSBUVIR;

AGED; ARTICLE; CHRONIC HEPATITIS C; CLINICAL PRACTICE; COHORT ANALYSIS; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; REGISTER; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; COMBINATION DRUG THERAPY; MIDDLE AGED; VERY ELDERLY; VIROLOGY;

AGED; AGED, 80 AND OVER; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; SOFOSBUVIR;

EID: 85039863556     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.11.009     Document Type: Article

References (17)

1. Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370 (2014), 1889–1898.
2. Afdhal, N., Reddy, K.R., Nelson, D.R., Lawitz, E., Gordon, S.C., Schiff, E., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370 (2014), 1483–1493.
3. Kowdley, K.V., Gordon, S.C., Reddy, K.R., Rossaro, L., Bernstein, D.E., Lawitz, E., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370 (2014), 1879–1888.
4. European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63 (2015), 199–236.
5. O'Brien, T.R., Feld, J.J., Kottilil, S., Pfeiffer, R.M., No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL. Hepatology 63 (2016), 28–30.
6. Curry MP, Bacon B, Dieterich D, Flamm SL, Guest L, Kowdley KV, et al. Effectiveness of 8 or 12 week LDV-SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network. Poster presented at the 66th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, Nov 13–17 2015.
7. Ioannou, G.N., Beste, L.A., Chang, M.F., Green, P.K., Lowey, E., Tsui, J.I., et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs national healthcare system. Gastroenterology 151 (2016), 457–471.
8. Terrault, N.A., Zeuzem, S., Di Bisceglie, A.M., Lim, J.K., Pockros, P.J., Frazier, L.M., et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated of sustained virologic response. Gastroenterology 151 (2016), 1131–1140.
9. Ingiliz, P., Christensen, S., Kimhofer, T., Hueppe, D., Lutz, T., Schewe, K., et al. Sofosbuvir and Ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus infection in HCV-mono-infected and HIV-HCV co-infected individuals- Results from the German hepatitis c cohort (GECCO-01). Clin Infect Dis 63 (2016), 1320–1324.
10. Backus, L.I., Belperio, P.S., Shahoumian, T.A., Loomis, T.P., Mole, L.A., Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice. Aliment Pharmacol Ther 44 (2016), 400–410.
11. Backus, L.I., Belperio, P.S., Shahoumian, T.A., Loomis, T.P., Mole, L.A., Real world effectiveness of ledipasvir/sofosbuvir in 4365 treatment-naïve genotype 1 hepatitis C infected patients. Hepatology 64 (2016), 405–416.
12. Wilder, J.M., Jeffers, L.J., Ravendhran, N., Shiffman, M.L., Poulos, J., Sulkowski, M.S., et al. Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. Hepatology 63 (2016), 437–444.
13. Welzel, T.M., Zeuzem, S., Dumas, E.O., Asselah, T., Shaw, D., Hazzan, R., et al. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. Lancet Gastroenterol Hepatol 2 (2017), 494–500.
14. Petersen J, Wursthorn K, Olah K, Lorenzen T, Plettenberg A, Unger S et al. Strong decrease of patients with advanced liver disease and more adherence problems to HCV therapy as DAA regimen enter third year of existence in Germany. Poster FRI-252 presented at The International Liver Congress 2017 of the European Association for the Study of the Liver. 2016 Apr 19–23; Barcelona, Spain.
15. Naggie, S., Cooper, C., Saag, M., Workowski, K., Ruane, P., Towner, W., et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med 373 (2015), 705–713.
16. Cloherty, G., Cohen, D., Sarrazin, C., Wedemeyer, H., Chevaliez, S., Herman, C., HCV RNA assay sensitivity impacts the management of patients treated with direct acting antivirals. Antivir Ther 20 (2015), 177–183.
17. Tapper, E.B., Bacon, B.R., Curry, M.P., Dieterich, D.T., Flamm, S.L., Guest, L.E., et al. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology 64 (2016), 1893–1899.